J
James M. Gold
Researcher at University of Maryland, Baltimore
Publications - 406
Citations - 35719
James M. Gold is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Schizophrenia & Cognition. The author has an hindex of 96, co-authored 383 publications receiving 32208 citations. Previous affiliations of James M. Gold include University of Maryland, Baltimore County & University of Mary.
Papers
More filters
Journal ArticleDOI
The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
Keith H. Nuechterlein,Michael F. Green,Robert S. Kern,Lyle E. Baade,M Deanna,Jonathan D. Cohen,Susan M. Essock,Wayne S. Fenton,Frederick J. Frese,James M. Gold,Terry E. Goldberg,Robert K. Heaton,Richard S.E. Keefe,Helena C. Kraemer,Raquelle I. Mesholam-Gately,Larry J. Seidman,Ellen Stover,Daniel R. Weinberger,Alexander S. Young,Steven Zalcman,Stephen R. Marder +20 more
TL;DR: The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia and may also aid evaluation of cognitive remediation strategies.
Journal ArticleDOI
Identification of separable cognitive factors in schizophrenia.
Keith H. Nuechterlein,M Deanna,James M. Gold,Terry E. Goldberg,Michael F. Green,Robert K. Heaton +5 more
TL;DR: Empirical evidence for cognitive performance dimensions in schizophrenia was evaluated and seven separable cognitive factors were replicable across studies and represent fundamental dimensions of cognitive deficit in schizophrenia: Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning and Memory, Visual Learning and memory, Reasoning and Problem Solving, and Verbal Comprehension.
Journal ArticleDOI
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Richard S.E. Keefe,Terry E. Goldberg,Philip D. Harvey,James M. Gold,Margaret P. Poe,Leigh Coughenour +5 more
TL;DR: The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer and to be highly correlated with the standard battery composite scores in patients and healthy controls.
Journal ArticleDOI
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe,Robert M. Bilder,Sonia M. Davis,Philip D. Harvey,Barton W. Palmer,James M. Gold,Herbert Y. Meltzer,Michael F. Green,George Capuano,T. Scott Stroup,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Clarence E. Davis,John K. Hsiao,Jeffrey A. Lieberman +16 more
TL;DR: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.
Journal ArticleDOI
Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia.
James M. Gold,Constance J. Carpenter,Christopher Randolph,Terry E. Goldberg,Daniel R. Weinberger +4 more
TL;DR: Regression analyses suggested that LN span performance predicted the WCST category achieved score, whereas measures of set shifting, verbal fluency, and attention were predictive of perseveration.